APA (7th ed.) Citation

RH, A., AA, A., & NT, A. (2025). Ripasudil, a Rho kinase inhibitor, attenuates testosterone-induced benign prostatic hyperplasia in rats: Targeting inflammation, oxidative stress, and Rho kinase pathways. Naunyn-Schmiedeberg's archives of pharmacology, 398(10), 14425. https://doi.org/10.1007/s00210-025-04215-7

Chicago Style (17th ed.) Citation

RH, Aljorani, Al-Zubaidy AA, and Abdali NT. "Ripasudil, a Rho Kinase Inhibitor, Attenuates Testosterone-induced Benign Prostatic Hyperplasia in Rats: Targeting Inflammation, Oxidative Stress, and Rho Kinase Pathways." Naunyn-Schmiedeberg's Archives of Pharmacology 398, no. 10 (2025): 14425. https://doi.org/10.1007/s00210-025-04215-7.

MLA (9th ed.) Citation

RH, Aljorani, et al. "Ripasudil, a Rho Kinase Inhibitor, Attenuates Testosterone-induced Benign Prostatic Hyperplasia in Rats: Targeting Inflammation, Oxidative Stress, and Rho Kinase Pathways." Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 398, no. 10, 2025, p. 14425, https://doi.org/10.1007/s00210-025-04215-7.